STERIS plc (NYSE: STE) has successfully finalized the acquisition of surgical and laparoscopic instrumentation, along with sterilization container assets, from BD (Becton, Dickinson and Company) (NYSE: BDX). This strategic move enriches STERIS’s Healthcare segment by adding strong and complementary brands. President and CEO Dan Carestio expressed enthusiasm, anticipating collaborative efforts to elevate customer value. Lazard provided financial advisory, and Thompson Hine LLP acted as legal counsel in this acquisition.
STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that it has completed the previously announced acquisition of the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from BD (Becton, Dickinson and Company) (NYSE:BDX).
“We are pleased to announce the closing of this acquisition, as the brands we are adding will strengthen, complement and expand STERIS’s product offerings within our Healthcare segment,” said Dan Carestio, President and Chief Executive Officer of STERIS. “We welcome these teams to STERIS and look forward to working together to enhance our value to our Customers.”
Lazard served as financial advisor to STERIS and Thompson Hine LLP served as legal counsel.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BioSpace
